Vijaya Diagnostic Centre Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Vijaya Diagnostic Centre Ltd trades at ₹1,502, in a confirmed uptrend and 18 weeks into that stage. That is +22.1% against its own 200-day average. It sits at 100% of a 52-week range of ₹870 to ₹1,504. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks.

Today the stock is in a confirmed uptrend — week 18 of stage 2, confirmed. At ₹1,502 it trades +22.1% versus its 200-day average and sits at 100% of its 52-week range (₹870–₹1,504).

Against the market, two honest reads. Cumulative: over the last 5.0 years the stock moved +140% while the NIFTY 500 moved +53% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Vijaya Diagnostic Centre Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: RE_RATED_EXPENSIVE. Our fortnightly research layers last read it on 22 August 2026.

Our read, 22 August 2026. Network maturation is lifting earnings, but the premium valuation requires expansion delivery without another capex or pricing reset.

From the numbers. Operating earnings are expanding, but valuation is already at the upper end of the available range. The normalized read confirms the premium rather than reversing it: margin is above its mid-cycle level and normalized…

From the price. Price stage 2, week 18 — above its 200-day line, relative strength rising.

From the research. Network maturation is lifting earnings, but the premium valuation requires expansion delivery without another capex or pricing reset.

🚨 Where they disagree. Operating earnings are expanding, but valuation is already at the upper end of the available range. The normalized read confirms the premium rather than reversing it: margin is above its mid-cycle level and normalized earnings produce an even higher multiple. The deterministic verdict is RE_RATED_EXPENSIVE: earnings must grow into the multiple.

What is proven. Network maturation is lifting earnings, but the premium valuation requires expansion delivery without another capex or pricing reset.

What is not proven yet. The thesis breaks if the next two reported quarters show revenue growth below the management growth aspiration while operating margin falls below the stated floor, because that would show that new-network investment is not being absorbed by mature-cluster operating leverage.

🚨 What would change our mind. The thesis breaks if the next two reported quarters show revenue growth below the management growth aspiration while operating margin falls below the stated floor, because that would show that new-network investment is not being absorbed by mature-cluster operating leverage.

Layer 1 read, 22 August 2026 — KEEP. Best engine in the batch — margins rising while it expands — but priced for 35% growth it is not delivering. Vijaya's diagnostics network is doing the hard thing: growing profit faster than sales while it is still spending on new centres. June 2026 sales rose 22.9% and profit 35.9%, with operating margin at 43% against 39% a year earlier, because mature centres grew 16% and the newest Bengaluru hub broke even in two quarters instead of the planned year. The cash is real too, at 1.55 times reported profit over three years, and I checked the trade cycle myself — customers pay at the counter and suppliers are financed for about 145 days, so the balance sheet is a source of cash, not a drain. The catch is the price and the promises: at 82.5 times earnings the shares are near the dearest they have ever…

What would change Layer 1’s mind. Sharpening the timeline's own falsification to this decision: what flips this to DROP is sales growth falling below 15% (milestone M1) at the same time as operating margin breaking the 40% floor (M2) in Q2 FY27 — that combination would prove new-centre spending is no longer being absorbed by mature-cluster operating leverage, which is the entire thesis. What would take it to P1 is FY27 capital spending coming in at or under the ₹150 crore year-to-date milestone (M3) with three or more hubs…

Layer 2 read, 22 August 2026 — BENCH. Demand is real, but too much new capacity and no valuation buffer make waiting safer. External evidence confirms volume-led diagnostics demand, matching Vijaya's reported growth and fast hub break-even. It also adds the decisive caution: sector capex is SUPPLY_FLOOD with institutions ABSENT, while Vijaya deferred pricing. The expensive normalized valuation is only a model read, but it leaves little room for that supply risk.

What would change Layer 2’s mind. Advance if a fresh sector-capital-flow block exits SUPPLY_FLOOD in the same quarter that Vijaya confirms its deferred price increase was taken.

The test written in advance. The thesis breaks if the next two reported quarters show revenue growth below the management growth aspiration while operating margin falls below the stated floor, because that would show that new-network investment is not being absorbed by mature-cluster operating leverage. — the thesis as written as stated by the next result.

The test written in advance. Capex and guidance credibility — Capex and guidance credibility FY27_capex_ytd_cr by the next result.

The test written in advance. Premium valuation — Premium valuation trailing_pe_percentile_10y by the next result.

What the company does. Revenue and profit grew in the latest quarter while operating margin remained above the stated floor. New hubs are reaching break-even early, supporting the spoke-and-hub rollout beyond Hyderabad. The valuation is already rich on both trailing and normalized earnings, so delivery matters more than further re-rating.

🚨 What the surface reading misses. The surface reading is: Jun 2026 was the highest revenue and net-profit quarter in the supplied eight-quarter series. The research reads it further: The higher quarter is accompanied by 43% operating margin, so the revenue advance did not require a collapse in reported operating profitability.

🚨 What the surface reading misses. The surface reading is: Revenue growth was 22.9% and net-profit growth was 35.9% year on year in Jun 2026. The research reads it further: Profit grew faster than revenue, consistent with reported operating leverage rather than a revenue-only expansion.

Lever 1 · Operating leverage — BUILDING. Mature centers and early hub break-even can absorb fixed costs as volume rises. What proves it keeps working: Mature-cluster operating leverage. It stops working if Mature-center growth slows while new-hub losses rise for two consecutive quarters.

Lever 3 · Management change — BUILDING. Planned hubs, spokes and backend infrastructure widen the addressable network beyond Hyderabad. What proves it keeps working: Phased network expansion. It stops working if Commissioning slips or the reported network count remains unreconciled.

Lever 5 · Regulatory approval — BUILDING. Integrated wellness and imaging packages can add volume and realization without relying on broad price hikes. What proves it keeps working: Wellness and integrated B2C mix. It stops working if Package demand weakens or discounting rises materially.

Lever 7 · Consolidation — BUILDING. Operating cash generation can fund the current expansion cycle, though free cash flow remains limited while capex is elevated. What proves it keeps working: Cash-funded buildout. It stops working if Operating cash conversion falls while capex remains elevated.

Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Vijaya Diagnostic Centre Ltd reported ₹231 Cr of revenue in the Jun 26 quarter, +22.9% year on year. That is the 12th straight quarter of year-on-year growth. Over 8 years it has compounded at 15.8% a year. The last full year, FY26, came in at ₹814 Cr. The last four reported quarters add to ₹857 Cr.

Why this happened. Cash conversion exceeds profit on both reported windows. The cash triangle shows that capex, rather than operating leakage, is the main use of operating cash.

FY26 revenue came in at ₹814 Cr (+19.5% on the year), capping 8 years at 15.8% compound. The latest quarter (Jun 26) printed ₹231 Cr, +22.9% year on year — the 12th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +20.3% growth against the decade's 15.8% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +20.2% over the last 4 quarters against +21.2%/yr over the last 8 — stabilising; TTM profit +23.8% vs +21.8%/yr — stabilising.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Vijaya Diagnostic Centre Ltd's operating margin is 43.0% in the Jun 26 quarter, +4.0 percentage points against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 32.0% to 44.0%. The current quarter sits inside that band.

Why this happened. The operating-leverage catapult applies because management attributes margin protection to fixed-cost absorption and phased launches. The read fails if new centers add costs faster than mature clusters add volume.

The latest quarter's operating margin is 43.0%, +4.0 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 32.0%–44.0%.

Why the margin moved: operating margin went +3.5 pp year on year while gross margin went +0.3 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Vijaya Diagnostic Centre Ltd earned ₹53.0 Cr of net profit in the Jun 26 quarter, +35.9% year on year. It is the 12th consecutive quarter of growth. Full-year FY26 profit was ₹173 Cr. The 8-year compound rate is 22.1%. That is 22.9% of the quarter's revenue. The same quarter a year earlier earned ₹39.0 Cr.

Jun 26 profit was ₹53.0 Cr, +35.9% year on year — the 12th consecutive quarter of growth. On the full year, FY26 printed ₹173 Cr (+20.1%), and the 8-year compound rate is 22.1%.

Why profit moved: revenue contributed +22.9% and the margin +4.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +24.6% vs revenue +20.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 155% of Vijaya Diagnostic Centre Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹271 Cr of operating cash against ₹173 Cr of profit. After ₹261 Cr of capital spending, ₹10.0 Cr was left as free cash.

FY26: operating cash of ₹271 Cr against reported profit of ₹173 Cr, leaving free cash of ₹10.0 Cr after ₹261 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 155% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 155%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.

Router verdict: the bigger cash user is investment — capital spending ran 3.5× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Vijaya Diagnostic Centre Ltd's cash conversion cycle runs −117 days in FY26, up from −118 days in FY21. Capital spending ran ₹772 Cr over the last 3 years. At FY26 sales of ₹814 Cr each day of that cycle holds about ₹2.2 Cr, so roughly ₹−261 Cr sits inside the business at any moment.

FY26: debtors at 9 days, inventory at 19 days — roughly 0.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −117 days, looser than FY21's −118.

The full loop: cash goes out to suppliers and production on day 0; stock waits 19 days to sell; customers pay about 9 days after that; and suppliers themselves are paid at 145 days — netting out to the −117-day cycle.

In money terms: at FY26 sales of ₹814 Cr, each day of the cycle holds about ₹2.2 Cr — so the −117-day loop keeps roughly ₹−261 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹772 Cr over the last 3 fiscal years against ₹220 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹35.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Vijaya Diagnostic Centre Ltd earns a ROCE of 21% in FY26. That is up from a trough of 18% in FY23. Return on invested capital clears the cost of that capital by +6.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 21.3% net margin on 0.54× asset turns.

FY26 ROCE is 21%, recovered from a FY23 trough of 18% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 21.3% net margin × 0.54× asset turns × 1.57× balance-sheet leverage ≈ 18.1% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 18.2% − 12.0% = a +6.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Vijaya Diagnostic Centre Ltd carries total debt of ₹423 Cr against shareholder equity of ₹957 Cr as of Mar 26, a debt-to-equity of 0.44. On the annual view that ratio went from 0.39 in FY22 to 0.44 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹423 Cr against shareholder equity of ₹957 Cr — a debt-to-equity of 0.44. On the annual view, debt-to-equity went from 0.39 (FY22) to 0.44 (FY26). Read the returns on this page with that leverage in mind.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 10.1 points of Vijaya Diagnostic Centre Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 31.6% of the company. Foreign institutions moved −8.4 points over the same window, to 11.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.

Why this happened. Management has outlined further hub and spoke additions, with Pune backend infrastructure and laboratory accreditation as dependencies. Early break-even evidence supports the rollout, but center-count reconciliation remains a monitoring issue.

The register over the last two years — Domestic institutions: +10.1 points over 8 quarters to 31.6%; Foreign institutions: −8.4 points over 8 quarters to 11.7%; Promoters: −1.4 points over 8 quarters to 52.5%.

Why the register moved: rotation — foreign institutions −8.4 points against domestic institutions +10.1 points over 8 quarters, with promoters −1.4 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Vijaya Diagnostic Centre Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

Why this happened. Management describes pathology and radiology as contributors and identifies wellness demand across retail and corporate customers. This is a mix lever, not a confirmed near-term price lever.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Vijaya Diagnostic Centre Ltd trades at 82.5× P/E, at the pricey end of its own range (96th percentile). Its long-run median P/E is 62.8×, measured across 5.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 82.5× is at the pricey end of its own range (96th percentile), against a long-run median of 62.8× measured over 5.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +20.0% against a +44.2% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the +19.1%/yr price move, ~−0.4%/yr came from earnings growth and ~+19.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

Solved at its 24 August 2026 price, Vijaya Diagnostic Centre Ltd was paying for profit growth of about 34.6% a year. Profit itself has compounded 22.1% a year over the past 8 years. Today the market pays 82.5× P/E, the 96th percentile of its own 5-year range.

What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is above what this company has actually delivered.

How to hold this number: it is a reading of one day's price, taken on 24 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Vijaya Diagnostic Centre Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 21.3% and holding. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

4-Factor Sector Score

55.7/100 — rank 5 of 9 in Diagnostics · 100% evidence confidence

Vijaya Diagnostic Centre Ltd scores 55.7 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 5. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 24 + 15.5 + 0.2 + 16 = 55.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Vijaya Diagnostic Centre Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Planned Price Increase Deferred · 7 August 2026. In May 2026, management said it would take roughly a 1% to 1.5% price hike in Q1 or Q2. In Aug 2026, management said no hike had been taken since the prior increase and that pricing would only be reassessed after Q2 and Q3, moving beyond the previously stated timing without explaining the delay; this changes realization assumptions.

Reported Center Count Does Not Reconcile With Additions · 7 August 2026. May 2026 reported 162 centers. By Aug 2026, management reported 166 centers but also said two hubs and six spokes had been commissioned to date, which would imply 170 centers from the prior reported base before any closures or reclassifications. The latest call did not explain the discrepancy, which matters for tracking network rollout and capex productivity.

FY27 Capital Expenditure Guidance Materially Revised Upward · 8 May 2026. Management consistently guided FY27 capital expenditure at INR 100-120 crores in both the Nov 2025 and Feb 2026 calls, covering the same planned expansion of 4-5 hubs and 10-12 spokes. In the May 2026 call, this was revised upward to INR 140-150 crores - a 17-50% increase - with management citing a new automated lab at Punjagutta, Hyderabad and higher center-level costs; the Punjagutta lab project had not been mentioned in either prior call, and the per-center capex for the same hub and spoke count also appears to have increased from the prior guided range. This unexplained revision would materially impact free cash flow projections and capital allocation models.

Expansion Strategy De-acceleration · 13 February 2026. In the November 2025 call, management signaled an aggressive expansion posture, stating that early break-evens in new geographies encouraged them to open "a lot more hubs" than previously planned. However, in the February 2026 call, they pivoted to a conservative stance for FY27, guiding for only 4-5 hubs (down from the 10 planned in FY26) and citing "operational bandwidth" constraints rather than capital availability as the reason to slow down hub additions. Earlier call (Nov 2025): “Bangalore... has broken even much earlier. So, that is kind of encouraging for us to open a lot more hubs than probably what we have mentioned.” Later call (Feb 2026): “For FY27, we will be seeing about 4-5 hubs... It is more in terms of ground-level operational challenges... The decision-making is not based on margin but on operational bandwidth and stabilization.”

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions